Immunotherapies have become a standard treatment for many patients with cancer. While these agents can be highly effective and associated with durable responses and improved long-term survival, they are also associated with a unique and potentially serious adverse event profile. Appropriate management of immune-related adverse events (irAEs) is essential for successful treatment with immunotherapies. To […]

While hundreds of clinical trials in lung cancer are completed each year, results from many trials will not be publicly released or published in a peer-reviewed journal. According to a study published in JAMA Network Open, results from as many as 25% of lung cancer clinical trials are never published. Researchers evaluated phase II and […]

While cyclin-dependent kinase (CDK)4/6 inhibitors have become a mainstay of treatment for patients with hormone receptor-positive (HR+), HER2-negative (HER2–) metastatic breast cancer (mBC), many patients still receive first-line treatment with chemotherapy, even in the absence of visceral crisis. Lacking head-to-head clinical trials comparing treatment approaches, a recent meta-analysis compared results from phase II and III […]

MorphoSys AG announced the combination of the CD19-targeted antibody tafasitamab with lenalidomide resulted in a statistically significant improvement in best objective response rate (ORR) compared with a real-world data-matched control cohort of lenalidomide alone in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This announcement was based on results from the retrospective observational matched-control cohort […]

According to a recent study conducted by Memorial Sloan Kettering Cancer Center, rates of Clostridioides difficile infection (CDI) are higher in patients with cancer than in healthy adults. This study used patient data from 93,566 patients in the SEER-Medicare database, including both healthy patients and patients with either solid tumors or hematologic malignancies diagnosed between […]

At Aptitude Health, we strive to understand patterns of care that affect cancer patients not enrolled in clinical trials. We identify factors influencing prescribing habits that shape best practices and positively impact patient care. CASES Summits are regional events where approximately 60 oncologists and hematologists from large community practices, along with leading scientific experts, gather […]

Guidelines from the National Comprehensive Cancer Network (NCCN) provide the foundation for treatment of breast cancer in the United States. However, as many as 1 in 5 patients receive treatment regimens that are not recommended by the NCCN, according to a recent study published in the Journal of the National Comprehensive Cancer Network. In this […]

At Aptitude Health, we strive to understand patterns of care that affect cancer patients not enrolled in clinical trials. We identify factors influencing prescribing habits that shape best practices and essentially get to the why. CASES Summits are regional events where approximately 60 oncologists and hematologists from large community practices, along with leading scientific experts, […]

In late August, the US Food and Drug Administration (FDA) granted priority review to the Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received one or more prior lines of therapy. Zanubrutinib had previously been given a Breakthrough Therapy designation for this indication. MCL is […]

On August 21, an application for the androgen receptor inhibitor enzalutamide was granted priority review by the United States Food and Drug Administration (FDA). Enzalutamide is currently approved for treatment of both nonmetastatic and metastatic castration-resistant prostate cancer (mCRPC). This new application adds an indication for enzalutamide as a treatment for patients with metastatic hormone-sensitive […]